Tech Company Financing Transactions
Impel NeuroPharma Funding Round
Impel NeuroPharma, based in Seattle, secured $67.5 million in funding from KKR, Norwest Venture Partners and 5AM Ventures.
Transaction Overview
Company Name
Announced On
12/7/2018
Transaction Type
Venture Equity
Amount
$67,500,000
Round
Series D
Investors
KKR (Lead Investor) (Ali Satvat)
Norwest Venture Partners (Lead Investor) (Robert Mittendorff)
venBio (Aaron Royston)
Proceeds Purpose
This financing will enable Impel to accelerate its existing clinical development portfolio in CNS disorders.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
201 Elliott Ave. West 260
Seattle, WA 98119
USA
Seattle, WA 98119
USA
Phone
Website
Email Address
Overview
Seattle-based Impel NeuroPharma was founded with a mission to enable drugs to bypass the blood brain barrier.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jon Congleton
Chief Medical Officer
Stephen Shrewsbury
Chief Scientific Officer
John Hoekman
Vice President
Michael Malafronte
VP - Bus. Development
Ellen Lubman
VP - Engineering
Scott Youmans
VP - Operations
Meghan Swardstrom
VP - Regulatory Affairs
Lynn Gold
Browse more venture capital transactions:
Prev: 12/7/2018: FireflyOn venture capital transaction
Next: 12/7/2018: EdCast venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs